Relapsed or Refractory Neuroblastoma
Conditions
Keywords
neuroblastoma, CAR-T
Brief summary
This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor(CAR)that will bind to tumour cells modified to express the GD2 protein on the cell surface. The study will determine if these modified T cells help the body's immune system eliminate tumour cells .The trial will also study the safety of treatment for CAR-T, how long CAR-T cells stay in the patient's body and the impact on this treatment for survival.
Detailed description
This is a single-arm, multicenter clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of relapsed or refractory neuroblastoma in children. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the following sequential phases: part A (screening, leukapheresis,cell product preparation and cytoreductive chemotherapy) and part B (treatment and follow-up). the follow-up period for each participant is approximately 35 months after the final CAR-T infusion. The total duration of the study are expected to be approximately 3 years. A total of 22 patients may be enrolled over a period of 3 years.
Interventions
BIOLOGICALGD2-targeted CAR-T cells
This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Sponsors
Nanjing Children's Hospital
Children's Hospital of Fudan University
Sinobioway Cell Therapy Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
1. Up to diagnostic criteria for relapsed or refractory neuroblastoma or high-risk patients，including: * Relapsed neuroblastoma : Children diagnosed with neuroblastoma who after standard treatment and remission, present lesions again and cannot reach complete remission with surgery. * Refractory neuroblastoma : ① Untreated patients that do not have to reach completes remission after 4 courses of chemotherapy in accordance with standard regimens nor reach complete remission with surgery. ② High-risk patients : Who have cell genetic variation, such as MYCN amplification or bone marrow metastasis. 2. Relapsed or Refractory Neuroblastoma: Target, of which expression may be intervened , discovered with Immunohistochemistry can be selected (GD2 +) (more than 50% of tumor cells is at least 2+ , adopting anti-GD2-mAb14G2a ). 3. Age: 1\ 14 years old of age at the time of enrollment, male or female. 4. Physical condition is good: ECOG score reaches 0 to 2 points. 5. Body weights greater than or equal to 10 kg. 6. White blood cell counts acuity≥ 1.0 x10\^9 / L. 7. Estimated survival times \> 90 days. 8. Voluntary participation, good compliance, can cooperate with the experimental observation and signed an informed consent form.
Exclusion criteria
1. Positive pregnancy tests. 2. Uncontrolled infection. 3. HIV infection, hepatitis B or C activity period. 4. Patients who need long-term immunosuppressive therapy (Such as allergies, autoimmune diseases, GVHD, etc.) 5. Combined activity of the central nervous system malignant tumor invasion. 6. Abnormal coagulation function, patients with severe thrombosis. 7. Organ failure 1. Heart：class Ⅱ or above. 2. Liver：class Ⅱ or above( Refer to Classification of Wuhan Conference (1983)). 3. Kidney: The second stage of renal insufficiency or above. 4. Lung: class Ⅱdecreased slightly or above. 5. Brain: The central nervous system transfer or have active lesions. 8. Patients who have participated in other clinical trials or other clinical trials in the past 30 days. 9. The researchers believe that the patient is not suitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy | 28d,56d,90d | The overall efficiency will be determined by the evaluation of CT/MRI scans and bone marrow biopsy. Assessment of tumor remission rate according to International Neuroblastoma Response Criteria. The overall efficiency = (complete remission (CR) number + the number of very good partial remission (VGPR) number + partial response (PR) number + mixed reaction (MR) number + no response (NR) number) / total number of cases receiving treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 3 years | From the test of the progression of disease progression or the interval between disease and death. |
| Overall survival | 3 years | For all patients, overall survival refers to the period from being included in the test group to death caused by any reason |
| Patients-based Quality of Life Evaluation | 3 years | According to EORTC quality of life measurement scale PedsQL4.0\_ children's quality of life of the core scale of the evaluation and comparison of physical condition before and after treatment. |
| 3°or above incidence rate of serious adverse reaction related to treatment | 3 years | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
China
Contacts
Primary ContactYongjun Fang, Ph.D
Outcome results
None listed